<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33273014</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1083-351X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>296</Volume>
            <PubDate>
              <Year>2021</Year>
              <Season>Jan-Jun</Season>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of biological chemistry</Title>
          <ISOAbbreviation>J Biol Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.</ArticleTitle>
        <Pagination>
          <StartPage>100157</StartPage>
          <MedlinePgn>100157</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">100157</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.RA120.014960</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0021-9258(20)00150-7</ELocationID>
        <Abstract>
          <AbstractText>Meningiomas (MNs), arising from the arachnoid/meningeal layer, are nonresponsive to chemotherapies, with ∼50% showing loss of the Neurofibromatosis 2 (NF2) tumor suppressor gene. Previously, we established NF2 loss activates mechanistic target of rapamycin complex 1 (mTORC1) and mechanistic target of rapamycin complex 2 (mTORC2) signaling, leading to clinical trials for NF2 and MN. Recently our omics studies identified activated ephrin (EPH) receptor and Src family kinases upon NF2 loss. Here, we report increased expression of several ligands in NF2-null human arachnoidal cells (ACs) and the MN cell line Ben-Men-1, particularly neuregulin-1/heregulin (NRG1), and confirm increased NRG1 secretion and activation of V-ERB-B avian erythroblastic leukemia viral oncogene homolog 3 (ERBB3) receptor kinase. Conditioned-medium from NF2-null ACs or exogenous NRG1 stimulated ERBB3, EPHA2, and mTORC1/2 signaling, suggesting pathway crosstalk. NF2-null cells treated with an ERBB3-neutralizing antibody partially downregulated mTOR pathway activation but showed no effect on viability. mTORC1/2 inhibitor treatment decreased NRG1 expression and downregulated ERBB3 while re-activating pAkt T308, suggesting a mechanism independent of NRG1-ERBB3 but likely involving activation of another upstream receptor kinase. Transcriptomics after mTORC1/2 inhibition confirmed decreased ERBB3/ERBB4 while revealing increased expression of insulin-like growth factor receptor 1 (IGF1R). Drug treatment co-targeting mTORC1/2 and IGF1R/insulin receptor attenuated pAkt T308 and showed synergistic effects on viability. Our findings indicate potential autocrine signaling where NF2 loss leads to secretion/activation of NRG1-ERBB3 signaling. mTORC1/2 inhibition downregulates NRG1-ERBB3, while upregulating pAkt T308 through an adaptive response involving IGF1R/insulin receptor and co-targeting these pathways may prove effective for treatment of NF2-deficient MN.</AbstractText>
          <CopyrightInformation>Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Beauchamp</LastName>
            <ForeName>Roberta L</ForeName>
            <Initials>RL</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Erdin</LastName>
            <ForeName>Serkan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Witt</LastName>
            <ForeName>Luke</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jordan</LastName>
            <ForeName>Justin T</ForeName>
            <Initials>JT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Plotkin</LastName>
            <ForeName>Scott R</ForeName>
            <Initials>SR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gusella</LastName>
            <ForeName>James F</ForeName>
            <Initials>JF</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ramesh</LastName>
            <ForeName>Vijaya</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: ramesh@helix.mgh.harvard.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 NS113854</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Biol Chem</MedlineTA>
        <NlmUniqueID>2985121R</NlmUniqueID>
        <ISSNLinking>0021-9258</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C545990">BMS 754807</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001583">Benzoxazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000623258">EPHA2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000597236">IGF1R protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C572449">INK128</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009025">Morpholines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000632121">NF2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C094131">NRG1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020890">Neuregulin-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D025581">Neurofibromin 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014227">Triazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0BSC3P4H5X</RegistryNumber>
          <NameOfSubstance UI="C585537">vistusertib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0VUA21238F</RegistryNumber>
          <NameOfSubstance UI="D000077341">Lapatinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1N3L70MDFX</RegistryNumber>
          <NameOfSubstance UI="C000589319">seribantumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C581292">ERBB3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D036104">Receptor, EphA2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D020893">Receptor, ErbB-3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D017526">Receptor, IGF Type 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>W36ZG6FT64</RegistryNumber>
          <NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019898" MajorTopicYN="N">Autocrine Communication</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001583" MajorTopicYN="N">Benzoxazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077341" MajorTopicYN="N">Lapatinib</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008577" MajorTopicYN="N">Meningeal Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008579" MajorTopicYN="N">Meningioma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009025" MajorTopicYN="N">Morpholines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020890" MajorTopicYN="N">Neuregulin-1</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025581" MajorTopicYN="N">Neurofibromin 2</DescriptorName>
          <QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D036104" MajorTopicYN="N">Receptor, EphA2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020893" MajorTopicYN="N">Receptor, ErbB-3</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017526" MajorTopicYN="N">Receptor, IGF Type 1</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Akt PKB</Keyword>
        <Keyword MajorTopicYN="Y">NF2</Keyword>
        <Keyword MajorTopicYN="Y">NRG1-ERBB3</Keyword>
        <Keyword MajorTopicYN="Y">brain tumor</Keyword>
        <Keyword MajorTopicYN="Y">dual mTORC1/mTORC2 inhibition</Keyword>
        <Keyword MajorTopicYN="Y">insulin-like growth factor (IGF) receptor 1</Keyword>
        <Keyword MajorTopicYN="Y">mammalian target of rapamycin (mTOR)</Keyword>
        <Keyword MajorTopicYN="Y">meningioma</Keyword>
        <Keyword MajorTopicYN="Y">signaling</Keyword>
        <Keyword MajorTopicYN="Y">tumor suppressor gene</Keyword>
      </KeywordList>
      <CoiStatement>Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>4</Day>
          <Hour>5</Hour>
          <Minute>37</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33273014</ArticleId>
        <ArticleId IdType="pmc">PMC7949095</ArticleId>
        <ArticleId IdType="doi">10.1074/jbc.RA120.014960</ArticleId>
        <ArticleId IdType="pii">S0021-9258(20)00150-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Blakeley J.O., Evans D.G., Adler J., Brackmann D., Chen R., Ferner R.E., Hanemann C.O., Harris G., Huson S.M., Jacob A., Kalamarides M., Karajannis M.A., Korf B.R., Mautner V.F., McClatchey A.I. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am. J. Med. Genet. A. 2012;158A:24–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3319201</ArticleId>
            <ArticleId IdType="pubmed">22140088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Evans D.G. Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II] Genet. Med. 2009;11:599–610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19652604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruggieri M., Pratico A.D., Evans D.G. Diagnosis, management, and new therapeutic options in childhood neurofibromatosis type 2 and related forms. Semin. Pediatr. Neurol. 2015;22:240–258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26706012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Claus E.B., Bondy M.L., Schildkraut J.M., Wiemels J.L., Wrensch M., Black P.M. Epidemiology of intracranial meningioma. Neurosurgery. 2005;57:1088–1095. discussion 1088–1095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16331155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleihues P., Louis D.N., Scheithauer B.W., Rorke L.B., Reifenberger G., Burger P.C., Cavenee W.K. The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 2002;61:215–225. discussion 226–219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11895036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apra C., Peyre M., Kalamarides M. Current treatment options for meningioma. Expert Rev. Neurother. 2018;18:241–249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29338455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McClatchey A.I., Fehon R.G. Merlin and the ERM proteins - regulators of receptor distribution and signaling at the cell cortex. Trends Cell Biol. 2009;19:198–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2796113</ArticleId>
            <ArticleId IdType="pubmed">19345106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaw R.J., Paez J.G., Curto M., Morse Pruit W., Saotome I., O'Bryan J.P., Gupta V., Ratner N., Der C.J., Jacks T., McClatchey A.I. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev. Cell. 2001;1:63–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11703924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi C., Wilker E.W., Yaffe M.B., Stemmer-Rachamimov A., Kissil J.L. Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2. Cancer Res. 2008;68:7932–7937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2707059</ArticleId>
            <ArticleId IdType="pubmed">18829550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>James M.F., Han S., Polizzano C., Plotkin S.R., Manning B.D., Stemmer-Rachamimov A.O., Gusella J.F., Ramesh V. NF2/Merlin is a novel negative regulator of mTOR complex 1 and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol. Cell Biol. 2009;29:4250–4261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2715803</ArticleId>
            <ArticleId IdType="pubmed">19451225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez-Lago M.A., Okada T., Murillo M.M., Socci N., Giancotti F.G. Loss of the tumor suppressor NF2/Merlin constitutively activates integrin-dependent mTORC1 signaling. Mol. Cell Biol. 2009;29:4235–4249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2715795</ArticleId>
            <ArticleId IdType="pubmed">19451229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamaratoglu F., Willecke M., Kango-Singh M., Nolo R., Hyun E., Tao C., Jafar-Nejad H., Halder G. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat. Cell Biol. 2006;8:27–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16341207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin F., Yu J., Zheng Y., Chen Q., Zhang N., Pan D. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell. 2013;154:1342–1355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3835333</ArticleId>
            <ArticleId IdType="pubmed">24012335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W., You L., Cooper J., Schiavon G., Pepe-Caprio A., Zhou L., Ishii R., Giovannini M., Hanemann C.O., Long S.B., Erdjument-Bromage H., Zhou P., Tempst P., Giancotti F.G. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell. 2010;140:477–490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2828953</ArticleId>
            <ArticleId IdType="pubmed">20178741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beauchamp R.L., James M.F., DeSouza P.A., Wagh V., Zhao W.N., Jordan J.T., Stemmer-Rachamimov A., Plotkin S.R., Gusella J.F., Haggarty S.J., Ramesh V. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. Oncotarget. 2015;6:16981–16997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4627286</ArticleId>
            <ArticleId IdType="pubmed">26219339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>James M.F., Lelke J.M., Maccollin M., Plotkin S.R., Stemmer-Rachamimov A.O., Ramesh V., Gusella J.F. Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol. Dis. 2008;29:278–292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2266821</ArticleId>
            <ArticleId IdType="pubmed">17962031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>James M.F., Stivison E., Beauchamp R., Han S., Li H., Wallace M.R., Gusella J.F., Stemmer-Rachamimov A.O., Ramesh V. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. Mol. Cancer Res. 2012;10:649–659.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22426462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giovannini M., Bonne N.X., Vitte J., Chareyre F., Tanaka K., Adams R., Fisher L.M., Valeyrie-Allanore L., Wolkenstein P., Goutagny S., Kalamarides M. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. Neuro Oncol. 2014;16:493–504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3956353</ArticleId>
            <ArticleId IdType="pubmed">24414536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goutagny S., Giovannini M., Kalamarides M. A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas. J. Neurooncol. 2017;133:443–445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28434114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goutagny S., Raymond E., Esposito-Farese M., Trunet S., Mawrin C., Bernardeschi D., Larroque B., Sterkers O., Giovannini M., Kalamarides M. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J. Neurooncol. 2015;122:313–320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25567352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Synodos for NF2 Consortium. Allaway R., Angus S.P., Beauchamp R.L., Blakeley J.O., Bott M., Burns S.S., Carlstedt A., Chang L.S., Chen X., Clapp D.W., Desouza P.A., Erdin S., Fernandez-Valle C., Guinney J., Gusella J.F. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS One. 2018;13</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5999111</ArticleId>
            <ArticleId IdType="pubmed">29897904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angus S.P., Oblinger J.L., Stuhlmiller T.J., DeSouza P.A., Beauchamp R.L., Witt L., Chen X., Jordan J.T., Gilbert T.S.K., Stemmer-Rachamimov A., Gusella J.F., Plotkin S.R., Haggarty S.J., Chang L.S., Johnson G.L. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol. 2018;20:1185–1196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6071664</ArticleId>
            <ArticleId IdType="pubmed">29982664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sagers J.E., Beauchamp R.L., Zhang Y., Vasilijic S., Wu L., DeSouza P., Seist R., Zhou W., Xu L., Ramesh V., Stankovic K.M. Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma. Sci. Rep. 2020;10:4211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7060236</ArticleId>
            <ArticleId IdType="pubmed">32144278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roskoski R., Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol. Res. 2019;139:395–411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30500458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harford-Wright E., Andre-Gregoire G., Jacobs K.A., Treps L., Le Gonidec S., Leclair H.M., Gonzalez-Diest S., Roux Q., Guillonneau F., Loussouarn D., Oliver L., Vallette F.M., Foufelle F., Valet P., Davenport A.P. Pharmacological targeting of apelin impairs glioblastoma growth. Brain. 2017;140:2939–2954.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5841205</ArticleId>
            <ArticleId IdType="pubmed">29053791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y., Lv S.Y., Ye W., Zhang L. Apelin/APJ system and cancer. Clin. Chim. Acta. 2016;457:112–116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27083318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ammoun S., Cunliffe C.H., Allen J.C., Chiriboga L., Giancotti F.G., Zagzag D., Hanemann C.O., Karajannis M.A. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol. 2010;12:834–843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2940674</ArticleId>
            <ArticleId IdType="pubmed">20511180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osorio D.S., Hu J., Mitchell C., Allen J.C., Stanek J., Hagiwara M., Karajannis M.A. Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2. J. Neurooncol. 2018;139:749–755.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6126973</ArticleId>
            <ArticleId IdType="pubmed">29948766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schoeberl B., Faber A.C., Li D., Liang M.C., Crosby K., Onsum M., Burenkova O., Pace E., Walton Z., Nie L., Fulgham A., Song Y., Nielsen U.B., Engelman J.A., Wong K.K. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 2010;70:2485–2494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2840205</ArticleId>
            <ArticleId IdType="pubmed">20215504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schoeberl B., Pace E.A., Fitzgerald J.B., Harms B.D., Xu L., Nie L., Linggi B., Kalra A., Paragas V., Bukhalid R., Grantcharova V., Kohli N., West K.A., Leszczyniecka M., Feldhaus M.J. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci. Signal. 2009;2:ra31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19567914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodrik-Outmezguine V.S., Chandarlapaty S., Pagano N.C., Poulikakos P.I., Scaltriti M., Moskatel E., Baselga J., Guichard S., Rosen N. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 2011;1:248–259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3227125</ArticleId>
            <ArticleId IdType="pubmed">22140653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fruman D.A., Chiu H., Hopkins B.D., Bagrodia S., Cantley L.C., Abraham R.T. The PI3K pathway in human disease. Cell. 2017;170:605–635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5726441</ArticleId>
            <ArticleId IdType="pubmed">28802037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ianevski A., Giri A.K., Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48:W488–W493.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7319457</ArticleId>
            <ArticleId IdType="pubmed">32246720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malyutina A., Majumder M.M., Wang W., Pessia A., Heckman C.A., Tang J. Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer. PLoS Comput. Biol. 2019;15</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6544320</ArticleId>
            <ArticleId IdType="pubmed">31107860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Appert-Collin A., Hubert P., Cremel G., Bennasroune A. Role of ErbB receptors in cancer cell migration and invasion. Front. Pharmacol. 2015;6:283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4657385</ArticleId>
            <ArticleId IdType="pubmed">26635612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capparelli C., Purwin T.J., Heilman S.A., Chervoneva I., McCue P.A., Berger A.C., Davies M.A., Gershenwald J.E., Krepler C., Aplin A.E. ErbB3 targeting enhances the effects of MEK inhibitor in wild-type BRAF/NRAS melanoma. Cancer Res. 2018;78:5680–5693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6168374</ArticleId>
            <ArticleId IdType="pubmed">30115691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capparelli C., Rosenbaum S., Berger A.C., Aplin A.E. Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma. J. Biol. Chem. 2015;290:24267–24277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4591813</ArticleId>
            <ArticleId IdType="pubmed">26269601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capparelli C., Rosenbaum S., Berman-Booty L.D., Salhi A., Gaborit N., Zhan T., Chervoneva I., Roszik J., Woodman S.E., Davies M.A., Setiady Y.Y., Osman I., Yarden Y., Aplin A.E. ErbB3-ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF/NRAS cutaneous melanomas. Cancer Res. 2015;75:3554–3567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4558382</ArticleId>
            <ArticleId IdType="pubmed">26206558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson T.R., Lee D.Y., Berry L., Shames D.S., Settleman J. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell. 2011;20:158–172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21840482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doherty J.K., Ongkeko W., Crawley B., Andalibi A., Ryan A.F. ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy. Otol. Neurotol. 2008;29:50–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18199957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lallemand D., Manent J., Couvelard A., Watilliaux A., Siena M., Chareyre F., Lampin A., Niwa-Kawakita M., Kalamarides M., Giovannini M. Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene. 2009;28:854–865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19029950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stonecypher M.S., Chaudhury A.R., Byer S.J., Carroll S.L. Neuregulin growth factors and their ErbB receptors form a potential signaling network for schwannoma tumorigenesis. J. Neuropathol. Exp. Neurol. 2006;65:162–175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16462207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karajannis M.A., Legault G., Hagiwara M., Ballas M.S., Brown K., Nusbaum A.O., Hochman T., Goldberg J.D., Koch K.M., Golfinos J.G., Roland J.T., Allen J.C. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol. 2012;14:1163–1170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3424212</ArticleId>
            <ArticleId IdType="pubmed">22844108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schoeberl B., Kudla A., Masson K., Kalra A., Curley M., Finn G., Pace E., Harms B., Kim J., Kearns J., Fulgham A., Burenkova O., Grantcharova V., Yarar D., Paragas V. Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121) NPJ Syst. Biol. Appl. 2017;3:16034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5516865</ArticleId>
            <ArticleId IdType="pubmed">28725482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boucher J., Kleinridders A., Kahn C.R. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb. Perspect. Biol. 2014;6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3941218</ArticleId>
            <ArticleId IdType="pubmed">24384568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon S.O., Shin S., Karreth F.A., Buel G.R., Jedrychowski M.P., Plas D.R., Dedhar S., Gygi S.P., Roux P.P., Dephoure N., Blenis J. Focal adhesion- and IGF1R-dependent survival and migratory pathways mediate tumor resistance to mTORC1/2 inhibition. Mol. Cell. 2017;67:512–527. e514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5698809</ArticleId>
            <ArticleId IdType="pubmed">28757207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrington L.S., Findlay G.M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., Barnett J., Leslie N.R., Cheng S., Shepherd P.R., Gout I., Downes C.P., Lamb R.F. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 2004;166:213–223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2172316</ArticleId>
            <ArticleId IdType="pubmed">15249583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah O.J., Wang Z., Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 2004;14:1650–1656.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15380067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsu P.P., Kang S.A., Rameseder J., Zhang Y., Ottina K.A., Lim D., Peterson T.R., Choi Y., Gray N.S., Yaffe M.B., Marto J.A., Sabatini D.M. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011;332:1317–1322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3177140</ArticleId>
            <ArticleId IdType="pubmed">21659604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Y., Yoon S.O., Poulogiannis G., Yang Q., Ma X.M., Villen J., Kubica N., Hoffman G.R., Cantley L.C., Gygi S.P., Blenis J. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science. 2011;332:1322–1326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3195509</ArticleId>
            <ArticleId IdType="pubmed">21659605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu P., Gan W., Inuzuka H., Lazorchak A.S., Gao D., Arojo O., Liu D., Wan L., Zhai B., Yu Y., Yuan M., Kim B.M., Shaik S., Menon S., Gygi S.P. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat. Cell Biol. 2013;15:1340–1350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3827117</ArticleId>
            <ArticleId IdType="pubmed">24161930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo Y., Liu L., Wu Y., Singh K., Su B., Zhang N., Liu X., Shen Y., Huang S. Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2. Oncotarget. 2015;6:4286–4298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4414190</ArticleId>
            <ArticleId IdType="pubmed">25738366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thoreen C.C., Kang S.A., Chang J.W., Liu Q., Zhang J., Gao Y., Reichling L.J., Sim T., Sabatini D.M., Gray N.S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 2009;284:8023–8032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2658096</ArticleId>
            <ArticleId IdType="pubmed">19150980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puttmann S., Senner V., Braune S., Hillmann B., Exeler R., Rickert C.H., Paulus W. Establishment of a benign meningioma cell line by hTERT-mediated immortalization. Lab. Invest. 2005;85:1163–1171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15965488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dobin A., Davis C.A., Schlesinger F., Drenkow J., Zaleski C., Jha S., Batut P., Chaisson M., Gingeras T.R. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3530905</ArticleId>
            <ArticleId IdType="pubmed">23104886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeLuca D.S., Levin J.Z., Sivachenko A., Fennell T., Nazaire M.D., Williams C., Reich M., Winckler W., Getz G. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics. 2012;28:1530–1532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3356847</ArticleId>
            <ArticleId IdType="pubmed">22539670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L., Wang S., Li W. RSeQC: quality control of RNA-seq experiments. Bioinformatics. 2012;28:2184–2185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22743226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H., Handsaker B., Wysoker A., Fennell T., Ruan J., Homer N., Marth G., Abecasis G., Durbin R., 1000 Genome Project Data Processing Subgroup  The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25:2078–2079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2723002</ArticleId>
            <ArticleId IdType="pubmed">19505943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robinson M.D., McCarthy D.J., Smyth G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2796818</ArticleId>
            <ArticleId IdType="pubmed">19910308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu K., Gualano R.C., Hibbs M.L., Anderson G.P., Bozinovski S. Epidermal growth factor receptor signaling to Erk1/2 and STATs control the intensity of the epithelial inflammatory responses to rhinovirus infection. J. Biol. Chem. 2008;283:9977–9985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18276593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiederhold T., Lee M.F., James M., Neujahr R., Smith N., Murthy A., Hartwig J., Gusella J.F., Ramesh V. Magicin, a novel cytoskeletal protein associates with the NF2 tumor suppressor merlin and Grb2. Oncogene. 2004;23:8815–8825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15467741</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
